BENTONVILLE, Ark., July 31,
2024 /PRNewswire/ -- SymBiosis and HealthTech
Arkansas have partnered to launch the biophyle Trial Accelerator, a
program designed to elevate healthcare innovations in Arkansas by connecting accomplished,
clinical-stage biotherapeutic innovations to Arkansas healthcare providers through clinical
trial opportunities or commercialization training programs.
Applications for the 2024 cohorts are now open. The program
offers two tracks: Track 1 is for clinical-stage companies with at
least one novel biotherapeutic asset in the oncology, immunology,
or cardiometabolic space and Track 2 is for Arkansas-based life science researchers
interested in learning how to move their research towards
commercialization.
Applicants for Track 1 will undergo an initial screening by
SymBiosis and HealthTech Arkansas. An advisory board comprised of
subject matter experts will review each company's application, with
all applicants receiving detailed feedback as to perceived
investibility and fit for the program. Applicants will also be
screened by clinical trial sites in Arkansas, and when there's mutual interest in
conducting a clinical trial, companies will be admitted to the
program on a rolling basis.
"Our vision for this program is to create a collaborative
environment where clinical-stage companies and local researchers
can work together to bring innovative treatments to market," said
Chidozie Ugwumba, Managing Partner at SymBiosis.
The goal of the Track 2 program is to provide Arkansas-based researchers with additional
knowledge, support, and network expansion to advance their research
toward commercialization. This program offers a structured platform
for delivering essential education, mentoring and grants access to
an extensive network of professional service organizations, subject
matter experts, and potential investors.
"Arkansas is fortunate to have
talented, accomplished, and well-funded life science researchers in
the state," said Jeff Stinson,
director at HealthTech Arkansas. "We look forward to bringing this
innovative training curriculum to them in an effort to help them
build their knowledge and networks and advance their innovations
towards the market."
The biophyle Trial Accelerator Program is supported by funding
from the Arkansas Economic Development Commission through a program
designed to increase acceleration activities in targeted industries
in the state.
More information about both tracks of the biophyle Trial
Accelerator can be found at biophyle.org.
ABOUT HEALTHTECH ARKANSAS
HealthTech Arkansas helps to
drive innovation for healthcare provider organizations through its
accelerator programs and through internal innovation programming.
Its flagship accelerator, HeartX, recruits worldwide for the most
accomplished cardiovascular-focused startups in the areas of
digital health, medical devices, and diagnostic platforms. Those
companies accepted into the program are guaranteed at least two
pilot projects or clinical trials from among the ten largest
hospitals and health systems in Arkansas. More information can be found at the
HealthTech Arkansas website:
https://www.healthtecharkansas.com/
ABOUT SYMBIOSIS CAPITAL MANAGEMENT, LLC
SymBiosis is
an investment firm focused on advancing biotherapeutics innovations
for serious and life-threatening diseases. The firm invests in
groundbreaking medicines across disease area, financing stage, and
geography, with a focus on programs in, or about to enter, human
trials. SymBiosis currently manages a portfolio of more than 30
investments and has significant, long-term capital commitments to
fund future investments. For more information, please visit
www.symbiosis.vc or follow us on LinkedIn.
For more information, contact:
Arielle Amrein
(479) 378-6655
381107@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biophyle-launches-accelerator-program-for-clinical-stage-companies-and-training-program-for-arkansas-biotech-entrepreneurs-302210371.html
SOURCE SymBiosis